It was recently reported that HORMAD1 is overexpressed in triple-negative breast cancer (TNBC), and HORMAD1 expression sensitizes breast cancer cells to homologous repair (HR)-defect targeting agents by contributing to homologous recombination deficiency [6]. Here, HORMAD1 is linked to breast carcinoma.